Vectibix FDA Approval History
FDA Approved: Yes (First approved September 27, 2006)
Brand name: Vectibix
Generic name: panitumumab
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Colorectal Cancer
Vectibix (panitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS) metastatic colorectal cancer.
Development timeline for Vectibix
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.